Jonas S Erjefält

Prof. Dr. Jonas S Erjefält

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
RKRoland Kolbeck
Roland Kolbeck
AKAlexander Kozhich
Alexander Kozhich
MKMasamichi Koike
Masamichi Koike
LPLi Peng
Li Peng
CACecilia K. Andersson
Cecilia K. Andersson
ACAnthony J. Coyle
Anthony J. Coyle

25 April 2016 in Nature Immunology
Verified
Journal Article
Closed access
SBSuzanne M Bal
Suzanne M Bal
JBJochem H Bernink
Jochem H Bernink
MNMaho Nagasawa
Maho Nagasawa
JGJelle Groot
Jelle Groot
MSMedya M Shikhagaie
Medya M Shikhagaie
XRXavier Romero Ros
Xavier Romero Ros

25 April 2016 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
JSJonathan S Silver
Jonathan S Silver
JKJennifer Kearley
Jennifer Kearley
ACAlan M Copenhaver
Alan M Copenhaver
CSCaroline Sanden
Caroline Sanden
MMMichiko Mori
Michiko Mori
AHAlison A Humbles
Alison A Humbles

1 March 2015 in Immunity
Verified
Journal Article
Closed access
JKJennifer Kearley
Jennifer Kearley
JSJonathan S. Silver
Jonathan S. Silver
CSCaroline Sanden
Caroline Sanden
ZLZheng Liu
Zheng Liu
ABAaron A. Berlin
Aaron A. Berlin
AHAlison A. Humbles
Alison A. Humbles

21 August 2007 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
SMSterghios A Moschos
Sterghios A Moschos
SJSimon W Jones
Simon W Jones
MPMark Michael Perry
Mark Michael Perry
AWAndrew Evan Williams
Andrew Evan Williams
JEJonas S Erjefält
Jonas S Erjefält
MLMark Andrew Lindsay
Mark Andrew Lindsay

3 March 1997 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MKMagnus Korsgren
Magnus Korsgren
JEJonas S Erjefält
Jonas S Erjefält
OKOlle Korsgren
Olle Korsgren
FSFrank Sundler
Frank Sundler
CPCarl G.A. Persson
Carl G.A. Persson
Immunoglobulins (Ig), particularly IgE, are believed to be crucially involved in the pathogenesis of asthma and, equally, in allergic models of the disease. To validate this paradigm we examined homozygous mutant C57BL/6 mice, which are B cell deficient, lacking all Ig. Mice were immunized intraperitoneally with 10 μg ovalbumin (OVA) plus alum, followed by daily (day 14–20) 30 min exposures to OVA aerosol (OVA/OVA group). Three control groups were run: OVA intraperitoneally plus saline (SAL) aerosol (OVA/SAL group); saline intraperitoneally plus saline aerosol; saline intraperitoneally plus OVA aerosol (n = 6–7). Lung and large airway tissues obtained 24 h after the last OVA or SAL exposure were examined by light microscopy and transmission electron microscopy (TEM). The Ig-deficient mice receiving OVA/ OVA treatment had swollen and discolored lungs and exhibited marked eosinophilia both in large airway subepithelial tissue (49.2 ± 12.0 cells/mm basement membrane [BM] versus OVA/ SAL control 1.2 ± 0.3 cells/mm BM; P <0.001), and perivascularly and peribronchially in the lung (49.3 ± 9.0 cells/unit area versus OVA/SAL control 2.6 ± 0.6 cells/unit area; P <0.001). The eosinophilia extended to the regional lymph nodes. TEM confirmed the subepithelial and perivascular localization of eosinophils. Mucus cells in large airway epithelium increased from 1.5 ± 0.8 (OVA/SAL mice) to 39.5 ± 5.7 cells/mm BM in OVA/OVA treated mice (P <0.001). OVA/SAL mice never differed from the other control groups. Corresponding experiments in wild-type mice (n = 6–7 in each group) showed qualitatively similar but less pronounced eosinophil and mucus cell changes. Macrophages and CD4+ T cells increased in lungs of all OVA/OVA-treated mice. Mast cell number did not differ but degranulation was detected only in OVA/OVA-treated wild-type mice. Immunization to OVA followed by OVA challenges thus cause eosinophil-rich inflammation in airways and lungs of mice without involvement of B cells and Ig.